MedWatch

Carb-X investment gives Snipr Biome validation before going to clinic

Snipr Biome has received a capital injection from antibiotics alliance Carb-X totaling up to USD 10.2m. CEO Christian Grøndahl thinks this will aid the company in its upcoming financing round.

Snipr Biome CEO Christian Grøndahl | Photo: EY / PR

Snipr Biome is delighted with the money recently placed in its account by global antibiotics alliance Carb-X, although the company was already keeping its head above water.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs